Abstract
The relative resistance of SARS-CoV-2 variants B.1.1.7 and B.1.351 to antibody neutralization has been described recently. We now report that another emergent variant from Brazil, P.1, is not only refractory to multiple neutralizing monoclonal antibodies, but also more resistant to neutralization by convalescent plasma (6.5 fold) and vaccinee sera (2.2-2.8 fold). The P.1 variant threatens current antibody therapies but less so the protective efficacy of our vaccines.
Competing Interest Statement
P.W., J.Y., M.N., Y.H., and D.D.H. are inventors on a provisional patent application on mAbs to SARS-CoV-2.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Posted March 02, 2021.
